Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701630 | 0.87 | PKM (0.47) | CNR2CYP3A4CNR1KMT2AKDM4E | |
| SCHEMBL3693268 | 0.80 | L3MBTL1 (0.40) | CNR2CNR1KMT2AMAPK1 | |
| SCHEMBL27602008 | 0.80 | CNR2 (0.48) | CNR2CYP3A4CNR1KMT2A | |
| SCHEMBL3705499 | 0.80 | CNR2 (0.44) | CNR2CNR1KMT2A | |
| SCHEMBL13819539 | 0.80 | CNR2 (0.40) | CNR2CNR1KMT2AKDM4E | |
| SCHEMBL13819538 | 0.80 | ALOX5 (0.41) | CNR2CNR1KMT2APTGS2PDE4D | |
| SCHEMBL3693693 | 0.76 | CNR2 (0.45) | CNR2CNR1PTGS2 | |
| SCHEMBL3694612 | 0.74 | CNR2 (0.42) | CNR2CNR1 | |
| SCHEMBL15393632 | 0.74 | CNR2 (0.36) | CNR2CYP3A4CNR1KMT2APDE4D | |
| SCHEMBL12121971 | 0.73 | PTGS2 (0.52) | CNR2CYP3A4MAPTKMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1652766-A | Topical formulations of resorcinol and cannabinoids and methods of administration thereof | IMMUGEN PHARMACEUTICALS INC (US) | 2005-08-10 | — | — | CN | disclosed |
| US-20040242870-A1 | Cannbichromene derivative; aids therapy | IMMUGEN PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040138315-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | IMMUGEN PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | US | disclosed |
| US-20030232101-A1 | Topical formulations of resorcinols and cannibinoids and methods of use | IMMUGEN PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030171372-A1 | Antiviral methods and compounds | IMMUGEN PHARMACEUTICALS, INC. (US) | 2003-09-11 | — | — | US | disclosed |
| US-6541510-B2 | Cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus, especially HIV. | IMMUGEN PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | disclosed |
| WO-2002026224-A9 | METHODS AND COMPOUNDS FOR INHIBITING EICOSANOID METABOLISM AND PLATELET AGGREGATION | IMMUGEN PHARMACEUTICALS INC (US) | 2003-02-20 | — | — | WO | disclosed |
| US-20020137802-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | IMMUGEN PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020068738-A1 | Antiviral methods and compounds | IMMUGEN PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002026224-A2 | METHODS AND COMPOUNDS FOR INHIBITING EICOSANOID METABOLISM AND PLATELET AGGREGATION | IMMUGEN PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026728-A2 | ANTIVIRAL METHODS AND COMPOUNDS | IMMUGEN PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171372-A1 | Antiviral methods and compounds | MAVS, CNR1, ZC3HAV1 | CNR2 5/4885CYP3A4 2052/4885MAPT 3386/4885 |
| US-20020068738-A1 | Antiviral methods and compounds | MAVS, CNR1, ZC3HAV1 | CNR2 5/4885CYP3A4 2052/4885MAPT 3386/4885 |
| US-20040242870-A1 | Cannbichromene derivative; aids therapy | CNR1, CNR2, MKI67 | CNR2 2/4885CYP3A4 1707/4885MAPT 1195/4885 |
| US-20020137802-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | PTGS1, PTGIS, PTGES | CNR2 9/4885CYP3A4 139/4885MAPT 4589/4885 |
| US-20030232101-A1 | Topical formulations of resorcinols and cannibinoids and methods of use | CNR2, CNR1, CXCL8 | CNR2 1/4885CYP3A4 817/4885MAPT 482/4885 |
| US-20040138315-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | PTGS1, PTGIS, PTGES | CNR2 9/4885CYP3A4 139/4885MAPT 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.